Enfagrow Premium Toddler Transitions
Allegations: Deceptively marketing products as “nutritionally appropriate” for children between nine and eighteen months
Enfamil Infant Formulas
Case Name (Date)
Martinez et al. v. Mead Johnson & Co., LLC
22-cv-213, C.D. Cal.
(Feb. 2022)
Product/Service
Several Enfamil infant formulas, including Gentlease, Enspire Gentlease, NeuroPro Gentlease, and NeuroPro Sensitive
Allegations
Misleadingly marketing formulas as “Milk-based Powder[s]” when the primary ingredient is dried corn syrup, which is a form of sugar
Status
Pending
Class-Action Tracker
Enfamil and Enfamil Premature
Allegations: Falsely marketing products as safe when they are dangerous for premature infants
Enfamil Infant Formula
Allegations: Failing to disclose that products contain toxic heavy metals
Enfamil Baby Formula Powders
Allegations: Products do not contain enough powder to make the advertised number of bottles
The Latest
CATrends: OTC Cold and Flu Meds Falsely Marketed as Nasal Decongestants
An FDA panel’s recent findings has led to a flood of lawsuits.
Researchers Call on FDA (Again) to Remove ‘Ineffective’ OTC Cold and Flu Medicines
Products marketed to clear up stuffy noses and relieve sinus congestion don’t work, researchers say.
Proposed Settlement Allows for Continued Deceptive Marketing of Neuriva
TINA.org files brief urging court to deny final approval of settlement that is unfair to consumers.
CATrends: Toddler Formula
It’s the perfect formula for a class-action lawsuit trend.
